醛固酮拮抗剂治疗与无心力衰竭的ST段抬高型心肌梗死患者死亡率:系统评价与荟萃分析
该系统评价与荟萃分析纳入10项随机临床试验共4147例无临床心力衰竭或LVEF大于40%的STEMI患者,评估醛固酮拮抗剂治疗的效果。结果显示,与对照相比,醛固酮拮抗剂治疗与死亡率降低相关(2.4% vs 3.9%;OR 0.62;95%CI 0.42-0.91;P=0.01),心肌梗死、新发充血性心力衰竭和室性心律失常风险无显著差异。治疗还与LVEF小幅显著升高(平均差1.58%;95%CI 0.18%-2.97%;P=0.03)和血清钾小幅升高(平均差0.07 mEq/L;95%CI 0.01-0.13 mEq/L;P=0.02)相关,血清肌酐无变化。作者结论认为,在LVEF大于40%或无心力衰竭的STEMI患者中,醛固酮拮抗剂治疗与死亡率获益相关。
要点
- 在无心力衰竭的STEMI患者中,醛固酮拮抗剂治疗与死亡率降低相关(2.4% vs 3.9%;OR 0.62;95%CI 0.42-0.91;P=0.01)。
- 醛固酮拮抗剂治疗与新发充血性心力衰竭风险无显著差异(4.3% vs 5.4%;OR 0.82;95%CI 0.56-1.20;P=0.31)。
- 醛固酮拮抗剂治疗与室性心律失常风险无显著差异(4.1% vs 5.1%;OR 0.76;95%CI 0.45-1.31;P=0.33)。
- 醛固酮拮抗剂治疗与LVEF小幅显著升高相关(平均差1.58%;95%CI 0.18%-2.97%;P=0.03)。
- 醛固酮拮抗剂治疗与血清钾小幅升高相关(平均差0.07 mEq/L;95%CI 0.01-0.13 mEq/L;P=0.02),血清肌酐无变化(标准化均数差1.4;95%CI -0.43至3.24;P=0.13)。
适用人群与场景
- 无临床心力衰竭或LVEF大于40%的ST段抬高型心肌梗死(STEMI)患者。
研究设计与关键结果
- 研究类型:系统评价与荟萃分析,纳入10项随机临床试验,共4147例独特患者。
- 主要终点:在无心力衰竭的STEMI患者中,醛固酮拮抗剂治疗与对照组相比,死亡率降低(2.4% vs 3.9%;OR 0.62;95%CI 0.42-0.91;P=0.01)。
- 次要终点:心肌梗死风险无显著差异(1.6% vs 1.5%;OR 1.03;95%CI 0.57-1.86;P=0.91);新发充血性心力衰竭风险无显著差异(4.3% vs 5.4%;OR 0.82;95%CI 0.56-1.20;P=0.31);室性心律失常风险无显著差异(4.1% vs 5.1%;OR 0.76;95%CI 0.45-1.31;P=0.33)。
- 其他终点:LVEF平均差1.58%(95%CI 0.18%-2.97%;P=0.03),血清钾平均差0.07 mEq/L(95%CI 0.01-0.13 mEq/L;P=0.02),血清肌酐标准化均数差1.4(95%CI -0.43至3.24;P=0.13)。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入随机临床试验,采用随机效应模型。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在无心力衰竭或LVEF大于40%的STEMI患者中,醛固酮拮抗剂治疗与死亡率降低相关,可能支持在这一人群中使用醛固酮拮抗剂。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Treatment with aldosterone antagonists is recommended and has been shown to have beneficial effects in patients with ST-segment elevation myocardial infarction (STEMI) and left ventricular ejection fraction (LVEF) less than 40%. However, the role of aldosterone antagonists in patients with ejection fraction greater than 40% or without congestive heart failure is not well known.
OBJECTIVES: To perform a systematic review and meta-analysis using standard techniques to determine the role of therapy with aldosterone antagonists in this patient population.
DATA SOURCES: PubMed, Embase, CINAHL, and Cochrane Central databases were searched and a manual search for relevant references from the selected articles and published reviews was performed from database inception through June 2017.
STUDY SELECTION: Randomized clinical trials that evaluated treatment with aldosterone antagonists in patients with STEMI without clinical heart failure or LVEF greater than 40% were included.
DATA EXTRACTION AND SYNTHESIS: Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were used to conduct and report the meta-analysis, which used a random-effects model. Two investigators independently performed the database search and agreed on the final study selection. A manual search was performed for relevant references from the selected articles and published reviews.
MAIN OUTCOMES AND MEASURES: The outcomes analyzed were mortality, new congestive heart failure, recurrent myocardial infarction, ventricular arrhythmia, and changes in LVEF, serum potassium level, and creatinine level at follow-up.
RESULTS: In all, 10 randomized clinical trials with a total of 4147 unique patients were included in the meta-analysis. In patients who presented with STEMI without heart failure, treatment with aldosterone antagonists compared with control was associated with lower risk of mortality (2.4% vs 3.9%; odds ratio [OR], 0.62; 95% CI, 0.42-0.91; P = .01) and similar risks of myocardial infarction (1.6% vs 1.5%; OR, 1.03; 95% CI, 0.57-1.86; P = .91), new congestive heart failure (4.3% vs 5.4%; OR, 0.82; 95% CI, 0.56-1.20; P = .31), and ventricular arrhythmia (4.1% vs 5.1%; OR, 0.76; 95% CI, 0.45-1.31; P = .33). Similarly, treatment with aldosterone antagonists compared with control was associated with a small yet significant increase in LVEF (mean difference, 1.58%; 95% CI, 0.18%-2.97%; P = .03), a small increase in serum potassium level (mean difference, 0.07 mEq/L; 95% CI, 0.01-0.13 mEq/L; P = .02), and no change in serum creatinine level (standardized mean difference, 1.4; 95% CI, -0.43 to 3.24; P = .13).
CONCLUSIONS AND RELEVANCE: Treatment with aldosterone antagonists is associated with a mortality benefit in patients with STEMI with LVEF greater than 40% or without heart failure.
参考来源
- Dahal K, Hendrani A, Sharma SP, et al. Aldosterone Antagonist Therapy and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Without Heart Failure: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018. PMID: 29799995. doi:10.1001/jamainternmed.2018.0850
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。